Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson’s disease – Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indicationsRandall W. Moreadith, Warren Olanow, Zhihao Fang et al.|European Polymer Journal|2016Cited by 175
Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpointYves Agid, Eduardo Tolosa, Eric Ahlskog et al.|Movement Disorders|1999Cited by 88